Top

Health and Quality of Life Outcomes

Published in:

Open Access 01-12-2005 | Research

The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population

Authors: Linda Abetz, Robert Arbuckle, Richard P Allen, Elena Mavraki, Jeffrey Kirsch

Published in: Health and Quality of Life Outcomes | Issue 1/2005

Abstract

Background

The aim of this study was to determine the reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a clinical trial setting.

Methods

Two matching, placebo-controlled, multinational studies assessing the effectiveness and safety of ropinirole for treating moderate-to-severe Restless Legs Syndrome (RLS) formed the basis of this psychometric assessment. Validity and reliability were assessed using baseline data. Responsiveness was determined using longitudinal data collected at baseline and 12 weeks.

Results

A total of 547 subjects formed the baseline validation population; 519 were used for assessing responsiveness (n = 284/263 and 271/248 for both studies, respectively). Construct validity assessment confirmed that an overall life impact score could be calculated. All item-scale correlations were = 0.4, except items 1 (r = 0.36) and 5 (r = 0.35) in one study. Floor and ceiling effects were minimal. Cronbach's alpha values were 0.82 and 0.87, respectively, confirming internal consistency reliability. Correlations with the International Restless Legs Syndrome Study Group's severity rating scale (International Restless Legs Scale; IRLS) were moderate (r = -0.68 and -0.67, respectively; p < 0.0001). The RLSQoL was able to discriminate between levels of sleep problems (p < 0.0001) and between levels of global health status determined by a Clinical Global Impression of severity (CGI-S) (p < 0.0001). Responsiveness was demonstrated by significant differences in overall life impact change scores between CGI improvement levels after 12 weeks (p < 0.0001).

Conclusion

The RLSQoL is a valid, reliable and responsive measure of quality of life for patients with RLS, in a clinical trial setting where group comparisons are anticipated.

Available only for authorised users

Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J: Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the national institutes of health. Sleep Med 2003, 4: 101–119. 10.1016/S1389-9457(03)00010-8PubMedCrossRef

Earley CP: Restless legs syndrome. N Engl J Med 2003, 348: 2103–2109. 10.1056/NEJMcp021288PubMedCrossRef

Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K: Prevalence and risk factors of RLS in an elderly population: the MEMO study. Memory and Morbidity in Augsburg Elderly. Neurology 2000, 54: 1064–1068.PubMedCrossRef

Allen RP, Earley CJ: Validation of the Johns Hopkins Restless Legs Severity Scale (JHRLSS). Sleep Med 2001, 2: 239–242. 10.1016/S1389-9457(00)00080-0PubMedCrossRef

Hening W, Walters AS, Allen RP, Montplaisir J, Myers A, Ferini-Strambi L: Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS Epidemiology, Symptoms, and Treatment) Primary Care study. Sleep Med 2004, 5: 237–246. 10.1016/j.sleep.2004.03.006PubMedCrossRef

Allen RP, Earley CJ: Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol 2001, 18: 128–147. 10.1097/00004691-200103000-00004PubMedCrossRef

Allen RP, La Buda MC, Becker P, Earley CJ: Family history study of the restless legs syndrome. Sleep Med 2002,3(Suppl):S3–7. 10.1016/S1389-9457(02)00140-5PubMedCrossRef

Desautels A, Turecki G, Montplaisir J, Sequeira A, Verner A, Rouleau GA: Identification of a major susceptibility locus for restless legs syndrome on chromosome 12q. Am J Hum Genet 2001, 69: 1266–1270. 10.1086/324649PubMedCentralPubMedCrossRef

Chen JT, Garcia PA, Alldredge BK: Zonisamide-induced restless legs syndrome. Neurology 2003, 60: 147.PubMedCrossRef

10.

Bonati MT, Ferini-Strambi L, Aridon P, Oldani A, Zucconi M, Casari G: Autosomal dominant restless legs syndrome maps on chromosome 14q. Brain 2003, 126: 1485–1492. 10.1093/brain/awg137PubMedCrossRef

11.

Trenkwalder C, Garcia-Borreguero D, Montagna P, Lainey E, de Weerd AW, Tidswell P, Saletu-Zyhlarz G, Telstad W, Ferini-Strambi L: Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12-week, randomised, placebo controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004, 75: 92–97.PubMedCentralPubMed

12.

Abetz L, Vallow S, Kirsch J, Allen R, Washburn T, Earley C: Validation of the Restless Legs Syndrome Quality of Life Questionnaire. Value Health 2005, 8: 157–167. 10.1111/j.1524-4733.2005.03010.xPubMedCrossRef

13.

Walters AS, Ondo WG, Dreykluft T, Grunstein R, Lee D, Sethi K, on behalf of the TREAT RLS 2 Study Group: Ropinirole is effective in the treatment of restless legs syndrome: TREAT RLS 2: a 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004, 19: 1414–1423. 10.1002/mds.20257PubMedCrossRef

14.

Allen RP, Kushida CA, Atkinson MJ: RLS QoL Consortium. Factor analysis of the International Restless Legs Syndrome Study Group's scale for restless legs severity. Sleep Med 2003, 4: 133–135. 10.1016/S1389-9457(02)00193-4PubMedCrossRef

15.

Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, Trenkwalder C, on behalf of the International Restless Legs Syndrome Study Group: Validation of the International Restless Legs Syndrome Study Group Rating Scale for restless legs syndrome. Sleep Med 2003, 4: 121–132. 10.1016/S1389-9457(02)00258-7PubMedCrossRef

16.

Hays RD, Stewart AL: Sleep measures. In Measuring Functioning and Well-Being. The Medical Outcomes Study Approach. Edited by: Stewart AL, Ware JE Jr. Durham and London: Duke University Press; 1992:235–259.

17.

Hays RD, Martin SA, Sesti AM, Spritzer KL: Psychometric properties of the medical outcomes study sleep measure. Sleep Med 2005, 6: 41–44. 10.1016/j.sleep.2004.07.006PubMedCrossRef

18.

Guy W Ed: Clinical Global Impression (CGI). In ECDEU Assessment Manual for Psychopharmacology. . Rockville, MD: US Department of Health and Human Services, Public Health Service, Alcohol Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch; 1976:218–222.

19.

Abetz L, Arbuckle R, Allen R, Garcia-Borreguero D, Hening W, Walters A, Mavraki E, Kirsch J: Validating the International Restless Legs Scale (IRLS) in a trial patient population. Poster presented at the 16th Annual Meeting of the British Sleep Society, Cambridge, UK; 2004:19–21.

20.

Campbell DT, Fiske DW: Convergent and discriminant validation by the multitrait-multimethod matrix. Psychol Bull 1959, 56: 81–105.PubMedCrossRef

21.

Bennett RM, Schein J, Kosinski MR, Hewitt DJ, Jordan DM, Rosenthal NR: Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 2005, 53: 519–527. 10.1002/art.21319PubMedCrossRef

22.

Kazis LE, Anderson JJ, Meenan RF: Effect Sizes for interpreting changes in health Status. Med Care 1989, 27: S178-S189.PubMedCrossRef

23.

Cohen J: Statistical Power Analysis for the Behavioral Sciences. 2nd edition. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.

24.

Guyatt GH, Osaba D, Wu AW, Wyrwich KW, Norman GR, the Clinical Significance Consensus Meeting Group: Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002, 77: 371–383.PubMedCrossRef

25.

Dunteman GH: Principal Components Analysis. Sage University Paper series on Quantitative Applications in the Social Sciences, Series No. 69. Newbury Park, CA: Sage; 1989.

26.

Scheitel SM, Boland BJ, Wollan PC, Silverstein MD: Patient-physician agreement about medical diagnosis and cardiovascular risk factors in the ambulatory general medication examination. Mayo Clin Proc 1996, 71: 1131–1137.PubMedCrossRef

27.

Abetz L, Shumaker S, Marciniak A, Thorsen H, Niero M, Kohlmann T: Agreement levels between clinicians' and patients' reports of health: results from an international study of postmenopausal women. Poster presented at The North American Menopause Society Meeting, Miami Beach, Florida, USA; 2003:19–21.

28.

Bouchet C, Guillemin F, Briancon S: Non-specific effects in longitudinal studies: impact on quality of life measures. J Clin Epidemiol 1996, 49: 15–20. 10.1016/0895-4356(95)00540-4PubMedCrossRef

Title: The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population
Authors: Linda Abetz
Robert Arbuckle
Richard P Allen
Elena Mavraki
Jeffrey Kirsch
Publication date: 01-12-2005
Publisher: BioMed Central
Published in: Health and Quality of Life Outcomes / Issue 1/2005
Electronic ISSN: 1477-7525
DOI: https://doi.org/10.1186/1477-7525-3-79

At a glance: The STEP trials

Springer Medicine

The reliability, validity and responsiveness of the Restless Legs Syndrome Quality of Life questionnaire (RLSQoL) in a trial population

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2005

Quality of life in post-menopausal osteoporosis

An investigation into the psychometric properties of the Hospital Anxiety and Depression Scale in patients with breast cancer

Response shift masks the treatment impact on patient reported outcomes (PROs): the example of individual quality of life in edentulous patients

Values for preventing influenza-related morbidity and vaccine adverse events in children

Quality of life in bipolar disorder: A review of the literature

Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review